Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axitinib + FOLFOX
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Axitinib + FOLFOX is a **combination regimen** consisting of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR 1, 2, and 3), together with the FOLFOX chemotherapy regimen, which includes folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. The combination targets tumor angiogenesis and directly cytotoxic effects on cancer cells. Axitinib acts by blocking VEGF-mediated signaling to inhibit angiogenesis in tumors, while FOLFOX impairs DNA replication, repair, and cell division in rapidly dividing cancer cells. This regimen has been investigated primarily for the treatment of advanced gastrointestinal cancers, particularly metastatic colorectal cancer, in phase I and II trials. The combination has been shown to be generally well tolerated, with adverse events manageable and pharmacokinetic interactions absent[1][3][5].
- Other names
- axitinib plus FOLFOXaxitinib + FOLFOXaxitinib combined with FOLFOX
02
Targets
DNAPDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on axitinib + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axitinib + FOLFOX.